- Home
- ME vs INBX Comparison
ME vs INBX Comparison
Compare ME & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ME
- INBX
- Stock Information
- Founded
- ME 2006
- INBX 2010
- Country
- ME United States
- INBX United States
- Employees
- ME N/A
- INBX N/A
- Industry
- ME Precision Instruments
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- ME Health Care
- INBX Health Care
- Exchange
- ME Nasdaq
- INBX Nasdaq
- Market Cap
- ME 168.9M
- INBX 232.2M
- IPO Year
- ME N/A
- INBX 2020
- Fundamental
- Price
- ME $0.30
- INBX $15.06
- Analyst Decision
- ME Hold
- INBX Hold
- Analyst Count
- ME 1
- INBX 1
- Target Price
- ME $0.47
- INBX N/A
- AVG Volume (30 Days)
- ME 2.8M
- INBX 96.5K
- Earning Date
- ME 08-08-2024
- INBX 08-13-2024
- Dividend Yield
- ME N/A
- INBX N/A
- EPS Growth
- ME N/A
- INBX N/A
- EPS
- ME N/A
- INBX 118.83
- Revenue
- ME $199,188,000.00
- INBX $1,687,000.00
- Revenue This Year
- ME $0.05
- INBX N/A
- Revenue Next Year
- ME $17.98
- INBX N/A
- P/E Ratio
- ME N/A
- INBX $0.13
- Revenue Growth
- ME N/A
- INBX 24.26
- 52 Week Low
- ME $0.30
- INBX $10.80
- 52 Week High
- ME $1.16
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- ME 35.07
- INBX 60.38
- Support Level
- ME $0.30
- INBX $13.69
- Resistance Level
- ME $0.32
- INBX $16.49
- Average True Range (ATR)
- ME 0.02
- INBX 0.75
- MACD
- ME 0.00
- INBX 0.33
- Stochastic Oscillator
- ME 5.43
- INBX 63.80
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.